» Articles » PMID: 38750164

A Large-scale Machine Learning Analysis of Inorganic Nanoparticles in Preclinical Cancer Research

Overview
Journal Nat Nanotechnol
Specialty Biotechnology
Date 2024 May 15
PMID 38750164
Authors
Affiliations
Soon will be listed here.
Abstract

Owing to their distinct physical and chemical properties, inorganic nanoparticles (NPs) have shown promising results in preclinical cancer therapy, but designing and engineering them for effective therapeutic purposes remains a challenge. Although a comprehensive database of inorganic NP research is not currently available, it is crucial for developing effective cancer therapies. In this context, machine learning (ML) has emerged as a transformative tool, but its adaptation to nanomedicine is hindered by inexistent or small datasets. Here we assembled a large database of inorganic NPs, comprising experimental datasets from 745 preclinical studies in cancer nanomedicine. Using descriptive statistics and explainable ML models we mined this database to gain knowledge of inorganic NP design patterns and inform future NP research for cancer treatment. Our analyses suggest that NP shape and therapy type are prominent features in determining in vivo efficacy, measured as a percentage of tumour reduction. Moreover, our database provides a large-scale open-access resource for discriminative ML that the broader nanotechnology community can utilize. Our work blueprints data mining for translational cancer research and offers evidence for standardizing NP reporting to accelerate and de-risk inorganic NP-based drug delivery, which may help to improve patient outcomes in clinical settings.

Citing Articles

The Role of Artificial Intelligence and Machine Learning in Accelerating the Discovery and Development of Nanomedicine.

Agrahari V, Choonara Y, Mosharraf M, Patel S, Zhang F Pharm Res. 2024; 41(12):2289-2297.

PMID: 39623144 DOI: 10.1007/s11095-024-03798-9.


Rational strategies for improving the efficiency of design and discovery of nanomedicines.

Shan X, Cai Y, Zhu B, Zhou L, Sun X, Xu X Nat Commun. 2024; 15(1):9990.

PMID: 39557860 PMC: 11574076. DOI: 10.1038/s41467-024-54265-3.


Twenty years of nanotoxicology: how AI could make the difference.

Campagnolo L, Lacconi V, Filippi J, Martinelli E Front Toxicol. 2024; 6:1470439.

PMID: 39376973 PMC: 11457712. DOI: 10.3389/ftox.2024.1470439.


Advancing cancer nanomedicine with machine learning.

Qin X, Lu T, Pang Z Acta Pharm Sin B. 2024; 14(9):4183-4185.

PMID: 39309501 PMC: 11413671. DOI: 10.1016/j.apsb.2024.06.018.

References
1.
Mendes B, Sousa D, Conniot J, Conde J . Nanomedicine-based strategies to target and modulate the tumor microenvironment. Trends Cancer. 2021; 7(9):847-862. DOI: 10.1016/j.trecan.2021.05.001. View

2.
Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

3.
Anselmo A, Mitragotri S . Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019; 4(3):e10143. PMC: 6764803. DOI: 10.1002/btm2.10143. View

4.
Anselmo A, Mitragotri S . Nanoparticles in the clinic: An update post COVID-19 vaccines. Bioeng Transl Med. 2021; 6(3):e10246. PMC: 8420572. DOI: 10.1002/btm2.10246. View

5.
Mendes B, Conniot J, Avital A, Yao D, Jiang X, Zhou X . Nanodelivery of nucleic acids. Nat Rev Methods Primers. 2022; 2. PMC: 9038125. DOI: 10.1038/s43586-022-00104-y. View